Pleomorphic giant cell carcinoma of the urinary bladder

Antonio Lopez-Beltran, Ana Blanca, Rodolfo Montironi, Liang Cheng, Juan C. Regueiro

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In this report, we present the clinicopathologic features of 8 cases of the pleomorphic giant cell variant of urothelial carcinoma. This is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumors. The pleomorphic giant cell component varied from 20% to 100% of the tumor specimen; in 2 cases, the pleomorphic giant cell component composed greater than 50% of the tumor with 1 case showing pure pleomorphic giant cell carcinoma. The architectural pattern of the tumor varied from infiltrating pleomorphic tumor with bizarre giant cells to solid expansile nests with discohesive growth pattern; a hypocellular desmoplastic stromal response was present in 2 cases (25%) with single cells in sclerotic stroma. At histology, giant, bizarre, anaplastic cells with frequent typical or atypical mitotic figures were present in all cases. Seven mixed cases had concurrent conventional high-grade urothelial carcinoma; 2 cases presented features of micropapillary or lymphoepithelioma-like urothelial carcinoma. Variable size intracytoplasmic vacuoles were present in 2 cases. All patients had advanced-stage cancer (≥pT3), and 6 (75%) had lymph node metastases. Immunohistochemical staining demonstrated that both pleomorphic giant cell and associated conventional urothelial carcinoma were positive for cytokeratins 7, CAM 5.2 and AE1/AE3, and epithelial membrane antigen; P63, thrombomodulin, and uroplakin III were positive in 6, 3, and 2 cases, respectively. Follow-up information was available in all cases (range, 6-74 months; mean, 20 months). Five of the patients died of disease from 6 to 17 months, and 2 patients were alive with metastases at 11 and 19 months. One patient had no evidence of disease at 74 months. In summary, pleomorphic giant cell is an aggressive variant of urothelial carcinoma associated with poor prognosis that presents at an advanced clinical stage. In limited samples, it may be misdiagnosed as secondary carcinoma or sarcoma, a pitfall of paramount importance for its clinical management.

Original languageEnglish (US)
Pages (from-to)1461-1466
Number of pages6
JournalHuman pathology
Volume40
Issue number10
DOIs
StatePublished - Oct 1 2009

Fingerprint

Giant Cell Carcinoma
Giant Cells
Urinary Bladder
Carcinoma
Neoplasms
Cellular Structures
Uroplakin III
Keratin-7
Neoplasm Metastasis
Thrombomodulin
Mucin-1
Vacuoles
Diagnostic Errors
Urinary Bladder Neoplasms
Sarcoma
Histology
Lymph Nodes
Staining and Labeling
Growth

Keywords

  • Bladder carcinoma
  • Giant cell carcinoma
  • Pleomorphic carcinoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Lopez-Beltran, A., Blanca, A., Montironi, R., Cheng, L., & Regueiro, J. C. (2009). Pleomorphic giant cell carcinoma of the urinary bladder. Human pathology, 40(10), 1461-1466. https://doi.org/10.1016/j.humpath.2009.02.016

Pleomorphic giant cell carcinoma of the urinary bladder. / Lopez-Beltran, Antonio; Blanca, Ana; Montironi, Rodolfo; Cheng, Liang; Regueiro, Juan C.

In: Human pathology, Vol. 40, No. 10, 01.10.2009, p. 1461-1466.

Research output: Contribution to journalArticle

Lopez-Beltran, A, Blanca, A, Montironi, R, Cheng, L & Regueiro, JC 2009, 'Pleomorphic giant cell carcinoma of the urinary bladder', Human pathology, vol. 40, no. 10, pp. 1461-1466. https://doi.org/10.1016/j.humpath.2009.02.016
Lopez-Beltran A, Blanca A, Montironi R, Cheng L, Regueiro JC. Pleomorphic giant cell carcinoma of the urinary bladder. Human pathology. 2009 Oct 1;40(10):1461-1466. https://doi.org/10.1016/j.humpath.2009.02.016
Lopez-Beltran, Antonio ; Blanca, Ana ; Montironi, Rodolfo ; Cheng, Liang ; Regueiro, Juan C. / Pleomorphic giant cell carcinoma of the urinary bladder. In: Human pathology. 2009 ; Vol. 40, No. 10. pp. 1461-1466.
@article{cabb4bd75d4d47fd824cafc140b38b30,
title = "Pleomorphic giant cell carcinoma of the urinary bladder",
abstract = "In this report, we present the clinicopathologic features of 8 cases of the pleomorphic giant cell variant of urothelial carcinoma. This is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumors. The pleomorphic giant cell component varied from 20{\%} to 100{\%} of the tumor specimen; in 2 cases, the pleomorphic giant cell component composed greater than 50{\%} of the tumor with 1 case showing pure pleomorphic giant cell carcinoma. The architectural pattern of the tumor varied from infiltrating pleomorphic tumor with bizarre giant cells to solid expansile nests with discohesive growth pattern; a hypocellular desmoplastic stromal response was present in 2 cases (25{\%}) with single cells in sclerotic stroma. At histology, giant, bizarre, anaplastic cells with frequent typical or atypical mitotic figures were present in all cases. Seven mixed cases had concurrent conventional high-grade urothelial carcinoma; 2 cases presented features of micropapillary or lymphoepithelioma-like urothelial carcinoma. Variable size intracytoplasmic vacuoles were present in 2 cases. All patients had advanced-stage cancer (≥pT3), and 6 (75{\%}) had lymph node metastases. Immunohistochemical staining demonstrated that both pleomorphic giant cell and associated conventional urothelial carcinoma were positive for cytokeratins 7, CAM 5.2 and AE1/AE3, and epithelial membrane antigen; P63, thrombomodulin, and uroplakin III were positive in 6, 3, and 2 cases, respectively. Follow-up information was available in all cases (range, 6-74 months; mean, 20 months). Five of the patients died of disease from 6 to 17 months, and 2 patients were alive with metastases at 11 and 19 months. One patient had no evidence of disease at 74 months. In summary, pleomorphic giant cell is an aggressive variant of urothelial carcinoma associated with poor prognosis that presents at an advanced clinical stage. In limited samples, it may be misdiagnosed as secondary carcinoma or sarcoma, a pitfall of paramount importance for its clinical management.",
keywords = "Bladder carcinoma, Giant cell carcinoma, Pleomorphic carcinoma",
author = "Antonio Lopez-Beltran and Ana Blanca and Rodolfo Montironi and Liang Cheng and Regueiro, {Juan C.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.humpath.2009.02.016",
language = "English (US)",
volume = "40",
pages = "1461--1466",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Pleomorphic giant cell carcinoma of the urinary bladder

AU - Lopez-Beltran, Antonio

AU - Blanca, Ana

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Regueiro, Juan C.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - In this report, we present the clinicopathologic features of 8 cases of the pleomorphic giant cell variant of urothelial carcinoma. This is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumors. The pleomorphic giant cell component varied from 20% to 100% of the tumor specimen; in 2 cases, the pleomorphic giant cell component composed greater than 50% of the tumor with 1 case showing pure pleomorphic giant cell carcinoma. The architectural pattern of the tumor varied from infiltrating pleomorphic tumor with bizarre giant cells to solid expansile nests with discohesive growth pattern; a hypocellular desmoplastic stromal response was present in 2 cases (25%) with single cells in sclerotic stroma. At histology, giant, bizarre, anaplastic cells with frequent typical or atypical mitotic figures were present in all cases. Seven mixed cases had concurrent conventional high-grade urothelial carcinoma; 2 cases presented features of micropapillary or lymphoepithelioma-like urothelial carcinoma. Variable size intracytoplasmic vacuoles were present in 2 cases. All patients had advanced-stage cancer (≥pT3), and 6 (75%) had lymph node metastases. Immunohistochemical staining demonstrated that both pleomorphic giant cell and associated conventional urothelial carcinoma were positive for cytokeratins 7, CAM 5.2 and AE1/AE3, and epithelial membrane antigen; P63, thrombomodulin, and uroplakin III were positive in 6, 3, and 2 cases, respectively. Follow-up information was available in all cases (range, 6-74 months; mean, 20 months). Five of the patients died of disease from 6 to 17 months, and 2 patients were alive with metastases at 11 and 19 months. One patient had no evidence of disease at 74 months. In summary, pleomorphic giant cell is an aggressive variant of urothelial carcinoma associated with poor prognosis that presents at an advanced clinical stage. In limited samples, it may be misdiagnosed as secondary carcinoma or sarcoma, a pitfall of paramount importance for its clinical management.

AB - In this report, we present the clinicopathologic features of 8 cases of the pleomorphic giant cell variant of urothelial carcinoma. This is a rare variant of bladder cancer recognized by the current World Health Organization classification of urologic tumors. The pleomorphic giant cell component varied from 20% to 100% of the tumor specimen; in 2 cases, the pleomorphic giant cell component composed greater than 50% of the tumor with 1 case showing pure pleomorphic giant cell carcinoma. The architectural pattern of the tumor varied from infiltrating pleomorphic tumor with bizarre giant cells to solid expansile nests with discohesive growth pattern; a hypocellular desmoplastic stromal response was present in 2 cases (25%) with single cells in sclerotic stroma. At histology, giant, bizarre, anaplastic cells with frequent typical or atypical mitotic figures were present in all cases. Seven mixed cases had concurrent conventional high-grade urothelial carcinoma; 2 cases presented features of micropapillary or lymphoepithelioma-like urothelial carcinoma. Variable size intracytoplasmic vacuoles were present in 2 cases. All patients had advanced-stage cancer (≥pT3), and 6 (75%) had lymph node metastases. Immunohistochemical staining demonstrated that both pleomorphic giant cell and associated conventional urothelial carcinoma were positive for cytokeratins 7, CAM 5.2 and AE1/AE3, and epithelial membrane antigen; P63, thrombomodulin, and uroplakin III were positive in 6, 3, and 2 cases, respectively. Follow-up information was available in all cases (range, 6-74 months; mean, 20 months). Five of the patients died of disease from 6 to 17 months, and 2 patients were alive with metastases at 11 and 19 months. One patient had no evidence of disease at 74 months. In summary, pleomorphic giant cell is an aggressive variant of urothelial carcinoma associated with poor prognosis that presents at an advanced clinical stage. In limited samples, it may be misdiagnosed as secondary carcinoma or sarcoma, a pitfall of paramount importance for its clinical management.

KW - Bladder carcinoma

KW - Giant cell carcinoma

KW - Pleomorphic carcinoma

UR - http://www.scopus.com/inward/record.url?scp=69949129360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949129360&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2009.02.016

DO - 10.1016/j.humpath.2009.02.016

M3 - Article

C2 - 19467692

AN - SCOPUS:69949129360

VL - 40

SP - 1461

EP - 1466

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -